INTRODUCTION {#sec0005}
============

Traumatic brain injury (TBI) is a leading cause of death and morbidity worldwide. The annual incidence of TBI with varying severity can be as high as 790 per 100,000 persons, according to a recent population-based study in New Zealand \[[@ref001]\]; in the US alone, ∼1.7 million people suffer from a TBI annually with 52,000 deaths as a result \[[@ref002]\], and ∼5.3 million people live with a TBI-related disability \[[@ref001]\]. TBI is an established risk factor for the development of neurodegeneration and dementia late in life \[[@ref005]\]. Among different types of TBI, repetitive mild brain traumas, as seen in professional athletes involved in contact sports and military veterans deployed in wars, often lead to chronic traumatic encephalopathy (CTE), a unique pattern of neurodegeneration characterized by focal perivascular to later widespread neurofibrillary tangles (NFTs) with less overt extracellular deposition of amyloid-*β* (A*β*) protein \[[@ref007]\].

Neurofibrillary pathology in CTE, as that seen in other neurodegenerative tauopathies including Alzheimer's disease (AD), is made up of abnormally hyperphosphorylated tau protein \[[@ref010]\]. Hyperphosphorylation of tau has been reported in a variety of TBI models, including repetitive mild TBI (r-mTBI), controlled cortical impact (CCI), and fluid percussion injury \[[@ref014]\], and is thus thought to play a role in etiopathogenesis of CTE \[[@ref018]\]. Moderate CCI has been shown to significantly increase, as measured by immunohistochemistry and western blots, the level of phospho-tau at multiple sites in ipsilateral hippocampus and fimbria in young adult 3xTg-AD mice \[[@ref014]\], which carry presenilin-1 knock-in mutation and overexpress human amyloid precursor protein with Swedish mutation and human tau with P301L mutation \[[@ref019]\]. In aged hTau transgenic mice which express all six isoforms of non-mutated human tau on a murine tau null background, close-head r-mTBI, a total of 5 impacts over 9 days, augments phospho-tau immunoreactivity in the somatodendritic compartment of neurons \[[@ref020]\]. Tau hyperphosphorylation was also observed in adult C57BL/6 mouse brain that sustained repetitive closed-head rotation/acceleration injury \[[@ref021]\], and in the brain of wild-type rats following fluid percussion injury \[[@ref018]\]. However, the molecular mechanism underlying the pathogenesis of neurofibrillary pathology of abnormal hyperphosphorylation of tau after TBI remains elusive.

The phosphorylation state of tau is physiologically orchestrated in a balanced manner by activities of protein kinases and protein phosphatases \[[@ref023]\] which, after TBI, are likely altered during the secondary damage initiated by direct mechanical tissue deformation \[[@ref025]\]. Given that protein phosphatase 2A (PP2A) accounts for about 70% of total tau phosphatase activity in adult human brain \[[@ref026]\], inhibition of PP2A may shift the balance between phosphorylation and dephosphorylation, leading to a net increase in tau phosphorylation. The SET protein, also known as template-activating factor 1*β* (TAF-1*β*) or inhibitor 2 of protein phosphatase 2A (I~2~^PP2A^), was first characterized as a nuclear phosphoprotein of the *set* gene that is associated with myeloid leukemogenesis \[[@ref027]\]. SET is a multifunctional protein. It has been shown to be involved in gene transcription, control of cell cycle, apoptosis, and cell migration \[[@ref029]\]. SET is significantly upregulated in AD brain \[[@ref034]\]. Notably, SET potently inhibits PP2A activity by acting with its catalytic subunit PP2Ac and thus is known as I~2~^PP2A^ \[[@ref035]\].

Despite its predominant localization in the nucleus, I~2~^PP2A^/SET translocates to the cell cytoplasm following its cleavage at N175 into N- and C-terminal fragments; both fragments potently inhibit PP2A and thereby promote hyperphosphorylation of tau \[[@ref036]\]. Asparaginyl endopeptidase (AEP), a lysosomal cysteine proteinase \[[@ref037]\] which is also known as legumain cleaves both I~2~^PP2A^ and tau and thereby indirectly leads to hyperphosphorylation of tau in AD brain \[[@ref038]\]. Thus, acidosis of the brain tissue could lead to hyperphosphorylation of tau through activation of AEP. TBI can lead to increase in lactate in the brain tissue \[[@ref025]\], which may facilitate the activation of AEP. However, it remains uncertain whether AEP plays a role in hyperphosphorylation of tau after TBI.

In the present study, we investigated the effect of r-mTBI on tau hyperphosphorylation and activation of AEP in 3xTg-AD mice. We found that AEP activation was associated with tau hyperphosphorylation following r-mTBI, probably via cleavage of I~2~^PP2A^ and its translocation from neuronal nucleus to the cytoplasm.

MATERIALS AND METHODS {#sec0010}
=====================

Animals {#sec0015}
-------

Adult female 3xTg-AD mice, 4--6 months of age, were used in this study; female 3xTg-AD mice start showing A*β* pathology at ∼9 months and tau pathology at ∼12 months of age \[[@ref019]\]. Mice were purchased from the Jackson Laboratory (Bar Harbor, ME), bred in our animal colony, and housed under a 12-h light/dark cycle, with *ad libitum* access to food and water. All animal procedures and use were *as per* the protocol approved by our Institutional Animal Care and Use Committee, in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals (revised February 15, 2015).

Protocols for traumatic brain injury {#sec0020}
------------------------------------

All TBI surgeries were performed by using the Impact One^TM^ stereotaxic impactor (Leica Biosystems, Richmond, IL). The r-mTBI was performed as described previously \[[@ref040]\]. Briefly, mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol (Sigma, St. Louis, MO) solution (250 mg/kg). The mouse head was shaved and then restrained using a stereotaxic frame and closed-head injury was delivered by a blunt metal tip, which was 5 mm in diameter, centered at midway of the sagittal suture and zeroed at the scalp. The scalp was mildly moisturized with saline and an electronic contact sensor was utilized to help optimize the vertical zero position on the scalp. The strike was set at 5.0 m/s velocity, 200 ms dwell time and 1.0 mm depth. Mice were subjected to a total of 5 impacts with inter-impact interval of 48 h. The sham control mice received anesthesia and stereotaxic restraint only. Mice were kept warm on a soft heating pad during surgery and until fully awake.

Brain tissue sampling {#sec0025}
---------------------

Given that the tau protein is rapidly dephosphorylated at many sites during postmortem interval at room temperature, as shown by us recently \[[@ref041]\], mice were sacrificed by cervical dislocation at 24 h after the fifth brain impact, and the brain was quickly dissected out and cooled down in a large volume of ice-cold phosphate-buffered saline (PBS), in which the brain regions from the left hemisphere were further dissected for western blots. The right hemisphere was immersion fixed in buffered 4% paraformaldehyde at room temperature for 48 h for immunohistochemistry.

For western blots, the forebrain was first separated from other brain regions, and then further dissected into two portions, i.e., the hippocampus and the remaining forebrain. These two brain parts were instantly frozen on dry ice and stored in --80°C until used.

Western blot analysis {#sec0030}
---------------------

The brain tissue was homogenized in pre-cooled buffer containing 50 mMTris-HCl, pH 7.4, 2 mM EDTA, 2 mM Na~3~VO~4~, 50 mM NaF, 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), and 10*μ*g/ml of each of aprotinin, leupeptin, and pepstatin A. The resulting 10% (w/v) homogenate was mixed with equal volume of 2×Lemaeli buffer, followed by boiling for 5 min. Protein concentration was measured by using A660 kit (Pierce, Rockford, IL). The samples were subjected to 10% SDS-PAGE and electro-transferred onto Immobilon-P membrane (Milipore, Bedford, MA). The blots were then probed with primary antibodies against total tau, phospho-taus, or AEP ([Table 1](#jad-64-jad180177-t001){ref-type="table"}), and developed with species-matched peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) and ECL kit (Pierce). The Multi Gauge V3.0 densitometry software (Fuji Photo Film Co., Ltd.) was utilized to quantify the density of protein bands in western blots. Table 1Primary antibodies employed in the present studyAntibodyTypeSpeciesSpecificitySite(s) recognizedWorking dilutionSource (catalog and/or reference)Anti-AEPPoly-SMouse AEP/1:500R&D Systems (AF2058)Anti-pS^199^tauPoly-RP-taupS^199^1:1000Invitrogen (44734G)Anti-pT^205^tauPoly-RP-taupT^205^1:1000Invitrogen (44738G)Anti-pT^212^tauPoly-RP-taupT^212^1:1000Invitrogen (44740G)Anti-pS^262^tauPoly-RP-taupS^262^1:1000Invitrogen (44750G)PHF-1Mono-MP-taupS^396/404^1:500Dr. P. DaviesAT8Mono-MP-taupS^202^/pT^205^1:1,000ThermoFisher Scientific (MN1020)Anti-pS^396^tauPoly-RP-taupS^396^1:1,000Invitrogen (44752G)134DPoly-RTotal tau; murine &human tau/1:1,000\[[@ref080]\]Anti-MAP2Mono-MMAP2/1:2,000Steinberger MonoclonalsIncorpoerated (SMI-52)Anti-Syn1Poly-RSynapsin-1/1:2,000Stressgen Biotechnologies (VAP-SV060)10E7Mono-MAnti-I~2~^PP2A^/1:1,000\[[@ref038]\]Anti GAPDHPoly-RGAPDH/1:3,000Santa-Cruz (sc-25778)*Poly*-, polyclonal; *Mono*-, monoclonal; *S*, sheep; *R*, rabbit; *M*, mouse; *P-tau*, phosphorylated tau

Immunohistochemistry {#sec0035}
--------------------

The right brain hemispheres of r-mTBI and sham control mice were embedded in paraffin. Adjacent serial sagittal sections, 6*μ*m in thickness and positioned at ∼1 mm lateral to the midline, were immunostained for phospho-tau at Ser^202^/Thr^205^ (AT8), Thr^212^, or Ser^396/404^ (PHF-1) separately. Briefly, sections were deparaffinized, rehydrated and subjected to antigen retrieval by boiling in pH 6.0 citrate buffer in a water bath for 30 min. Sections were then washed in PBS, subjected to permeabilization and removal of endogenous peroxidase activity, blocked in normal goat serum, and incubated with primary antibodies (see [Table 1](#jad-64-jad180177-t001){ref-type="table"}) overnight at 4°C. After washing in PBS, the sections were incubated with species-matched horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h, washed and simultaneously developed in 0.05% diaminobenzidine (Sigma) plus 0.015% hydrogen peroxide (Fisher Scientific, Fair Lawn, NJ) to guarantee an identical development condition. Sections were counterstained with Mayer's hematoxylin, dehydrated in ascending concentrations of ethanol, cleared in Histoclear (National Diagnostics, Atlanta, GA), and covered with coverslips.

Photomicrogaphs were taken on a Nikon 90i digital microscope by using identical imaging settings for quantitation of immnunoreactivity with NIH's ImageJ software package. For comparison of staining between groups, signals were extracted from images by using the color threshold function with identical settings.

Immunofluorescence {#sec0040}
------------------

Sagittal paraffin-embedded sections at ∼1 mm lateral to the midline were deparaffinized, rehydrated and subjected to immunofluorescence staining. Briefly, sections were blocked in normal goat serum, and incubated overnight at 4°C with primary antibodies against phospho-tau, I~2~^PP2A^, microtubule-associated protein 2 (MAP-2), synapsin-1 or AEP ([Table 1](#jad-64-jad180177-t001){ref-type="table"}), or a combination of two for double immunofluorescence staining. After washing in PBS, the sections were incubated with species-matched fluorophore-conjugated secondary antibodies (1:1,000 each, Life Technologies, Rockford, IL) plus TO-PRO 3 iodide (1:1,000, Thermo Fisher Scientific) for nuclear staining at room temperature for 2 h. Sections were washed in PBS and covered with anti-fade mounting medium.

Fluorescence photomicrographs were taken using a TCS-SP2 laser scanning confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany). For quantification of immunofluorescent staining, images were taken with a 100× objective lens; 4--6 randomly selected visual fields in each of at least two sections per animal were employed and the measures averaged for individual animal. Quantification of fluorescence immunoreactivity was performed using ImageJ, and the criteria for signal thresholding, *Moments* in most cases or Yen's arithmetic when suitable, were kept consistent across groups. Percent area occupied by a particular marker was calculated for each animal using the sum of immunopositive areas and that of the total areas.

Statistical analysis {#sec0045}
--------------------

Quantitative data were analyzed using the GraphPad Prism 5.0 software package (GraphPad Software, Inc., La Jolla, CA). Data were plotted as scattered dot plots with mean±SEM. Unpaired *t* test, with Welch's correction in the case of unequal variance, was used for comparison between two groups. Pearson correlation was used to analyze the relation of tau phosphorylation level with the level of active AEP. *p* \< 0.05 was considered statistically significant.

RESULTS {#sec0050}
=======

Tau is hyperphosphorylated in mouse brain after r-mTBI {#sec0055}
------------------------------------------------------

To identify the effect of r-mTBI on tau hyperphosphorylation in 3xTg-AD mice, we first examined levels of phosphorylations at multiple sites of tau using western blots. We found that the level of phospho-tau, when normalized with total tau was increased at Thr^205^ and pSer^262^ in hippocampus and at PHF-1 (pSer^396/404^) site in both the hippocampus and forebrain ([Fig. 1](#jad-64-jad180177-g001){ref-type="fig"}A, B). In forebrains of mice with r-mTBI, levels of Thr^205^ and pSer^262^ showed a trend of increase ([Fig. 1](#jad-64-jad180177-g001){ref-type="fig"}B). Immunohistochemical staining showed over 27% increase in phospho-tau immunoreactivity in fimbria in brains with r-mTBI when compared to that in the sham control, as detected by PHF-1 and by antibody against pSer^396^-tau ([Fig. 2](#jad-64-jad180177-g002){ref-type="fig"}A, B). The pSer^396^-tau immunoreactivity was also visible in subiculum as clusters of dots but with a markedly lower density than the clusters seen in fimbria ([Fig. 2](#jad-64-jad180177-g002){ref-type="fig"}B). However, neither fimbria nor other brain regions showed AT8 (pSer^202^/pThr^205^) or anti-pThr^212^ tau immunoreactivity ([Fig. 2](#jad-64-jad180177-g002){ref-type="fig"}A). These results indicate that tau is hyperphosphorylated at selected sites in mouse brain after r-mTBI. Fig. 1Tau phosphorylation increases at multiple sites in the brain following r-mTBI in 3xTg-AD mice. Adult female 3xTg-AD mice, 4--- months of age, were subjected to repetitive mild closed-head brain impacts, totaling five with 48-h inter-impact intervals, and sacrificed 24 h after the final impact. A) Representative western blots showing the level of indicated proteins/phosphorylation sites. B) Densitometric quantification of the blots. Among the phosphorylation sites examined, tau was hyperphosphorylated at pThr^205^, pSer^262^ and PHF-1 (pSer^396/404^) sites. Data are presented as scatter dot plots with mean±SEM (*n* = 6-7 mice each) and analyzed using unpaired *t* test, with Welch's correction in the case of unequal variance. Fig. 2Tau is hyperphosphorylated in fimbria of the hippocampus in 3xTg-AD mice after r-mTBI. A) Representative images showing immunohistochemical staining of sagittal brain sections with antibodies PHF-1, AT8 (pSer^202^/pThr^205^) or anti-pThr^212^-tau. Fimbria showed easily visible PHF-1 immunoreactivity, and quantification revealed significantly more immunoreactivity in r-mTBI group than sham control group. No staining was detected by AT8 or anti-pThr^212^-tau. No primary antibody control for PHF-1 staining exhibited no staining. B) Immunofluorescence staining with anti-pSer^396^-tau. Immunoreactivity was mostly seen in fimbria, though subiculum also showed sparse staining. In addition, quantification which was performed by using images taken with a 20× objective lens showed more immunoreactivity in fimbria in r-mTBI group than in sham controls. Data are expressed as scattered dot plots with mean±SEM (*n* = 6-7 mice/group) and analyzed with unpaired Student *t* test. Scale bar = 500*μ*m (A), 50*μ*m (insert and B).

Level of activated AEP increases and correlates with tau hyperphosphorylation after r-mTBI {#sec0060}
------------------------------------------------------------------------------------------

AEP is synthesized as a 56 kDa zymogen (pro-AEP) and is autocatalytically cleaved to produce 36 kDa active enzyme (active AEP) under acidic conditions \[[@ref042]\]. To study the role of AEP in tau pathogenesis after TBI, we analyzed the level of active AEP (36 kDa) by western blots. We found that AEP was significantly more activated in the hippocampi of r-mTBI mice than sham control animals ([Fig. 3](#jad-64-jad180177-g003){ref-type="fig"}A); in forebrain, though the increase in the level of activated AEP did not reach statistical significance, it showed a trend ([Fig. 3](#jad-64-jad180177-g003){ref-type="fig"}A). Intriguingly, the level of active AEP was positively correlated with the level of tau phosphorylated at Thr^205^ and PHF-1 sites ([Fig. 3](#jad-64-jad180177-g003){ref-type="fig"}B). These data suggest the involvement of AEP in tau hyperphosphorylation in r-mTBI. Fig. 3Activation of AEP is increased in the brain and correlated with the level of hyperphosphorylated tau following r-mTBI in 3xTg-AD mice. A) Representative western blots and quantification showing the level of active AEP (aAEP). Data are expressed as scattered dot plots with mean±SEM (*n* = 6-7 mice/group) and analyzed with unpaired Student *t* test. B) Pearson correlation of aAEP level to the level of indicated phospho-tau in the hippocampus.

Translocation of I~2~^PP2A^ to the cytoplasm links AEP activation to tau hyperphosphorylation after r-mTBI {#sec0065}
----------------------------------------------------------------------------------------------------------

Immunofluorescent staining showed that translocation of I~2~^PP2A^ to the neuronal cytoplasm in cerebral cortex was significantly increased after r-mTBI whereas sham control animals exhibited I~2~^PP2A^ immunoreactivity mostly in the neuronal nuclei ([Fig. 4](#jad-64-jad180177-g004){ref-type="fig"}A, B). Double immunofluorescent staining revealed that increase in translocation of I~2~^PP2A^ was associated with increase in the expression of AEP in the neuronal cytoplasm ([Fig. 4](#jad-64-jad180177-g004){ref-type="fig"}C), and that cytoplasmic I~2~^PP2A^ was colocalized with tau hyperphosphorylated at Thr^205^, pSer^262^ and pSer^396^ ([Fig. 5](#jad-64-jad180177-g005){ref-type="fig"}). These data suggest that AEP could be involved in translocation of I~2~^PP2A^ to the neuronal cytoplasm and consequently tau hyperphosphorylation in r-mTBI. Fig. 4r-mTBI promotes translocation of I~2~^PP2A^/SET from neuronal nucleus to the cytoplasm in 3xTg-AD mice. A) Representative immunofluorescence staining showing translocation of inhibitor 2 of protein phosphatase 2A (I~2~^PP2A^ or SET) to neuronal cytoplasm in cerebral cortex. B) Quantification of I~2~^PP2A^ translocation, as percentage of cytoplasmic over total I~2~^PP2A^ immunoreactivity within the same visual field. Data are expressed as scattered dot plots with mean±SEM (*n* = 6-7 mice/group) and analyzed with unpaired Student *t* test. C) Double immunofluorescent staining of I~2~^PP2A^ and AEP in brain sections. Lysosome-like AEP-positive puncta and I~2~^PP2A^ coexisted in the cytoplasm of neurons (arrows) in brains with r-mTBI; neurons in sham control brains showed fewer AEP puncta (hollow arrowhead). Scale bar = 10*μ*m for all images. Fig. 5Translocated I~2~^PP2A^/SET is colocalized with hyperphosphorylated tau in the neuronal cytoplasm in cerebral cortex of 3xTg-AD mice with r-mTBI. Brain sections were fluorescently dual immuno-stained for I~2~^PP2A^ and phospho-tau. Translocated I~2~^PP2A^ colocalized with pThr^205^-tau, pSer^396^-tau and with pSer^262^-tau in the cytoplasm of neurons (arrows). However, there was no somatodendritic phospho-tau staining in neurons where cytoplasmic I~2~^PP2A^ was absent (filled arrowheads). Scale bar = 10*μ*m for all images.

Mice with r-mTBI show neurodegeneration {#sec0070}
---------------------------------------

To study neurodegeneration induced by r-mTBI, we performed double-immunofluorescent staining of brain sections for MAP-2 and synapsin-1. MAP-2 is a neuronal somatodendritic marker, and synapsin-1 is a presynaptic marker. The mice with r-mTBI exhibited 21% decrease in MAP-2 immuno-positive area in the cerebral cortex and 24% reduction in density of synapsin-1 positive presynaptic puncta in the hippocampus as compared to sham control animals ([Fig. 6](#jad-64-jad180177-g006){ref-type="fig"}A, B). These data indicate neurodegeneration after r-mTBI in mice. Fig. 6Repetitive mild TBI induces dendritic and synaptic degeneration in 3xTg-AD mice. Brain sections were double immunofluorescent stained for microtubule-associated protein 2 (MAP2) and synapsin-1 (Syn-1), as somatodendritic and presynaptic markers, respectively. Representative photomicrographs show the staining and quantification in cerebral cortex (A) and the striatum radiatum of hippocampal CA1 subfield (B). Data are expressed as scattered dot plots with mean±SEM (*n* = 6-7 mice/group) and analyzed with unpaired Student *t* test. Scale bar = 10*μ*m for all.

DISCUSSION {#sec0075}
==========

Repetitive mild TBI in mice in which diffuse shearing and tearing of axons and vessels occur similar to that in mTBI in humans \[[@ref015]\], is a suitable model to study the pathophysiology of CTE. Although CTE is proposed to represent a progressive neurodegeneration associated with alterations of tau, TDP-43 and A*β* proteins that occur as a consequence of r-mTBI \[[@ref006]\], it is histopathologically characterized by hyperphosphorylated tau inclusions ranging in severity from focal perivascular NFTs to severe tau pathology affecting widespread brain regions \[[@ref008]\]. Approximately one-third of individuals who sustain a single moderate to severe TBI show abundant and widely distributed NFTs many years after the injury \[[@ref046]\]. Although majority of TBI cases belong to mild TBI \[[@ref001]\], repetitive mild TBI has been associated with profound neurofibrillary pathology in the brain in retired professional American football players \[[@ref009]\]. The nature of TBI-induced neurodegeneration has led to the belief that hyperphosphorylation of tau represents a pivotal biochemical event in pathogenesis of CTE \[[@ref045]\].

Murine tau is less prone to hyperphosphorylation and aggregation than human tau after TBI \[[@ref045]\]. Although r-mTBI in aged hTau transgenic mice, which overexpress all six isoforms of wild-type human tau, showed overtly augmented tau immunoreactivity \[[@ref020]\], the same r-mTBI model in C57BL/6 mice showed neither elevated tau immunohistochemical staining nor biochemically increased level of phospho-tau compared to sham control animals in the chronic phase \[[@ref015]\]. In the present study, we employed 3xTg-AD mice which overexpress mutated human tau (P301L tau) as an animal model, and we detected biochemically an increased level of tau phosphorylation at Thr^205^, Ser^262^, and PHF-1 (Ser^396/404^) sites 24 h after the fifth of a total of five mild closed-head impacts in these animals. However, we detected no significant change in total tau level in r-mTBI group as compared to sham control animals by western blots. Immunohistochemical staining confirmed increased level of phosphorylated tau (pSer^396/404^) despite that the immunoreactivity was seen mainly in fimbria of the hippocampus. This is consistent, at least in part, with the findings of Tran and colleagues who showed substantial increase of phospho-tau immunoreactivity, including pSer^396^, in ipsilateral fimbria after moderate CCI in 3xTg-AD mice \[[@ref014]\]. We observed occasional hyperphosphorylation of tau at Thr^205^, Ser^262^ or pSer^396^ site by immunofluorescent staining in the neuronal somatodendritic compartment; nevertheless, we only detected immunohistochemically a marked increase in tau hyperphosphorylated at pSer^396/404^ site in fimbria, an exclusively axonal area. This may be due to aggregation of pSer^396/404^-tau \[[@ref047]\] which is enriched in axons and/or less rapid postmortem dephosphorylation of tau at PHF-1 than at Ser^262^ and Thr^205^ \[[@ref041]\], two more preferred sites for PP2A \[[@ref026]\].

Molecular mechanisms underlying the development of tau pathology after TBI remain to be unraveled. Since the phosphorylation state of tau is governed by balanced regulation of tau protein kinases and phosphatases, one possible mechanism of etiopathogenesis of tau in TBI could be the dysregulation of proteases, such as calpain and AEP that can modulate tau kinases/phosphatases, as a result of initial mechanical insult to the brain and/or secondary damage that follows \[[@ref025]\]. Both calpain and AEP have been shown to play a role in tau hyperphosphorylation in AD and related tauopathies \[[@ref038]\]. Although the role of calpain activation in TBI-induced neurodegeneration has been extensively studied \[[@ref052]\], no previous study has explored the role of brain AEP in TBI.

The activity of PP2A, the major tau phosphatase in the brain \[[@ref026]\], is inhibited by full length \[[@ref057]\] and also N-and C-terminal fragments of I~2~^PP2A^ which are known to induce Alzheimer-like pathology *in vivo*. AEP is the main cysteine proteinase involved in the cleavage of I~2~^PP2A^ and may thus contribute to tau hyperphosphorylation in AD brain \[[@ref038]\]. Calcium overload and release of excitatory amino acids, two cardinal initiating events in secondary damage after TBI, can lead to ischemia, hypoxia and increase in lactate \[[@ref025]\] and thereby acidosis of the brain tissue \[[@ref059]\] and lysosomal abnormalities \[[@ref065]\], conditions in which AEP can be activated and facilitated to cleave I~2~^PP2A^ \[[@ref066]\]. In the present study, we found a significant increase in the level of active AEP which was correlated to tau hyperphosphorylation after r-mTB in mice. Furthermore, we found a marked cytoplasmic translocation of I~2~^PP2A^, and more importantly its colocalization with hyperphosphorylated tau, suggesting a potential increase in inhibition of PP2A activity which favors tau hyperphosphorylation in the neuronal cytoplasm \[[@ref068]\]. Taken together, these data suggest a role of AEP-I~2~^PP2A^-PP2A pathway in hyperphosphorylation of tau in TBI.

Neurofibrillary pathology correlates with the severity of dementia in AD \[[@ref069]\], and hyperphosphorylated oligomeric tau has been shown to represent neurotoxic \[[@ref071]\] and seeding-competent \[[@ref072]\] tau species. Given that the development of neurofibrillary pathology and neurodegeneration are long-term phenomena in neurodegenerative diseases \[[@ref076]\], persistent neuronal load of hyperphosphorylated tau may thus possibly represent a pathophysiological event that causes neural degeneration after TBI. Using MAP-2 as a marker for dendritic damage or plasticity \[[@ref077]\] and synapsin-1 as a presynaptic marker, in the present study we found that dendritc and synaptic degeneration was evident 24 h after the final impact of a total of five brain impacts. Based on the indicated role of AEP activation and subsequent cleavage of I~2~^PP2A^ in hyperphosphorylation of tau in cell models and in AD brain \[[@ref038]\] and the findings of the present study, we propose that activation of AEP as a consequence of primary/secondary brain damage represents a mechanism by which TBI leads to tau hyperphosphorylation that may eventually contribute to CTE pathology ([Fig. 7](#jad-64-jad180177-g007){ref-type="fig"}). Fig. 7Proposed model demonstrating the involvement of AEP activation in tau hyperphosphorylation in TBI. TBI induces acidosis of the brain tissue, which increases the level of active AEP and its translocation from neuronal lysosomes to the cytoplasm and the nucleus. Active AEP cleaves I~2~^PP2A^ into amino- and carboxy-terminal fragments \[[@ref038]\], both of which are translocated to the cytoplasm and inhibit PP2A activity \[[@ref036]\], leading to hyperphosphorylation of tau. I~2~^PP2A^, inhibitor 2 of protein phosphatase 2A; I~2NTF~, amino-terminal fragment of I~2~^PP2A^; I~2CTF~, carboxy-terminal fragment of I~2~^PP2A^; *P-tau*, hyperphosphorylated tau.

A characteristic pattern of tau pathology in human CTE is perivascular foci of neurofibrillary tangles at the depth of sulci, which are thought to represent the early accumulation of tau aggregates in CTE brains \[[@ref008]\]. This pattern of neurofibrillary pathology is not recapitulated in rodent models \[[@ref045]\] because the rodent brain differs significantly from the human brain in anatomical architecture. Importantly, the ratio of white matter versus gray matter in rodent brain is only 10% as compared to 60% in human brain; and the rodent cerebral cortex does not have convoluted folds, in contrast to extensive sulci in the human cerebral cortex. Recent studies employing postmortem CTE brains suggest that disruption of blood-brain barrier \[[@ref078]\] and/or axons \[[@ref079]\] underlying the sulci, which are vulnerable to damage by shearing and tearing forces at brain concussion \[[@ref025]\], may account for the start of tau pathology in perivascular foci at the depth of sulci. In the present study, we observed significantly increased accumulation of phospho-tau in fimbria and occasional cytoplasmic accumulation of phospho-tau in the cerebral cortex in mice with r-mTBI, a pattern different from that seen in human CTE. This distinction may be a consequence of different anatomical and physiological features of the mouse brain from the human brain. The role of AEP in downstream pathophysiological events of blood-brain barrier damage and/or axonal disruption could be explored in future studies.

In short, in the present study we found that the level of active AEP was increased in brains of 3xTg-AD mice with r-mTBI, and tau hyperphosphorylation correlated well with the level of active AEP and it was colocalized with I~2~^PP2A^ that was translocated from neuronal nucleus to the cytoplasm. In addition, the sites of tau which showed hyperphosphorylation and colocalized with cytoplasmic I~2~^PP2A^, i.e., Thr^205^, Ser^262^ and PHF-1 (Ser^396/404^), are known to be sensitive sites for dephosphorylation by PP2A \[[@ref041]\]. These data suggest that AEP may potentially play an important role in pathogenesis of tau in CTE. The role of AEP in TBI could be investigated in future studies by observing the dynamic change of tau hyperphosphorylation and neurofibrillary pathology on a chronic basis.
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